Research programme: anti-HIV agents - Immusol/Schering-Plough
Alternative Names: Anti-HIV agents research programme - Immusol/Schering-PloughLatest Information Update: 24 Aug 2007
At a glance
- Originator Immusol; Schering-Plough
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 24 Aug 2007 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
- 22 Feb 2005 NeoGenesis has been acquired and merged into Schering-Plough
- 08 Nov 2001 Preclinical development for HIV infections treatment in USA (Unknown route)